These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31465737)

  • 1. Physicochemical Stability of Monoclonal Antibodies: A Review.
    Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V
    J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrogen-deuterium exchange mass spectrometry as an emerging analytical tool for stabilization and formulation development of therapeutic monoclonal antibodies.
    Majumdar R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2015 Feb; 104(2):327-45. PubMed ID: 25354868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical Stability Studies of Antibody-Drug Conjugates (ADCs) Under Stressed Conditions.
    Adem YT
    Methods Mol Biol; 2020; 2078():301-311. PubMed ID: 31643066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of Protein Pharmaceuticals: Recent Advances.
    Manning MC; Holcomb RE; Payne RW; Stillahn JM; Connolly BD; Katayama DS; Liu H; Matsuura JE; Murphy BM; Henry CS; Crommelin DJA
    Pharm Res; 2024 Jul; 41(7):1301-1367. PubMed ID: 38937372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing antibody stability: Effects of stressors on Ipilimumab from the commercial formulation to diluted solutions.
    Fongaro B; Cian V; Gabaldo F; De Paoli G; Miolo G; Polverino de Laureto P
    Eur J Pharm Biopharm; 2022 Jul; 176():54-74. PubMed ID: 35595030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Physicochemical Stability of Monoclonal Antibodies in a Simulated Subcutaneous Environment.
    Jogdeo CM; Bhattacharya DS; Lin V; Kolhe P; Badkar A
    J Pharm Sci; 2024 Jul; 113(7):1854-1864. PubMed ID: 38341129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative buffer systems in biopharmaceutical formulations and their effect on protein stability.
    Lebar B; Zidar M; Mravljak J; Šink R; Žula A; Pajk S
    Acta Pharm; 2024 Sep; 74(3):479-493. PubMed ID: 39279529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Peptide Microarrays for Fast and Informative Profiling of Therapeutic Antibody Formulation Conditions.
    Austerberry J; Edwards J; Eyes T; Derrick JP
    Mol Pharm; 2021 Nov; 18(11):4131-4139. PubMed ID: 34658237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shipping-Induced Aggregation in Therapeutic Antibodies: Utilization of a Scale-Down Model to Assess Degradation in Monoclonal Antibodies.
    Fleischman ML; Chung J; Paul EP; Lewus RA
    J Pharm Sci; 2017 Apr; 106(4):994-1000. PubMed ID: 27964939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and Administration of Biological Medicinal Products".
    Krämer I; Thiesen J; Astier A
    Pharm Res; 2020 Aug; 37(8):159. PubMed ID: 32743712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Affinity-Capture Self-Interaction Nanoparticle Spectroscopy in Predicting Protein Stability, Especially for Co-Formulated Antibodies.
    Zhou M; Yan Z; Li H; Liu X; Sun P
    Pharm Res; 2021 Apr; 38(4):721-732. PubMed ID: 33754257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Hydrogen Exchange Mass Spectrometry as a Stability-Indicating Method for Formulation Excipient Screening for an IgG4 Monoclonal Antibody.
    Toth RT; Pace SE; Mills BJ; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2018 Apr; 107(4):1009-1019. PubMed ID: 29269271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability testing in monoclonal antibodies.
    Kaur H
    Crit Rev Biotechnol; 2021 Aug; 41(5):692-714. PubMed ID: 33596751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing Robust Monoclonal Antibody Drug Products: Pitfalls of Simplistic Approaches for Stability Prediction.
    Rembert KB; Gokarn YR; Saluja A
    J Pharm Sci; 2024 Aug; 113(8):2296-2304. PubMed ID: 38556000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing monoclonal antibody formulations in arginine glutamate solutions using
    Kheddo P; Cliff MJ; Uddin S; van der Walle CF; Golovanov AP
    MAbs; 2016 Oct; 8(7):1245-1258. PubMed ID: 27589351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technical decision-making with higher order structure data: specific binding of a nonionic detergent perturbs higher order structure of a therapeutic monoclonal antibody.
    Budyak IL; Doyle BL; Weiss WF
    J Pharm Sci; 2015 Apr; 104(4):1543-7. PubMed ID: 25545760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of excipients is a poor predictor for aggregation kinetics of biopharmaceutical proteins.
    Zalar M; Svilenov HL; Golovanov AP
    Eur J Pharm Biopharm; 2020 Jun; 151():127-136. PubMed ID: 32283214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary Packages cannot Protect Liquid Biopharmaceutical Formulations from Dropping-Induced Degradation.
    Fang WJ; Liu JW; Gao H; Qian YC; Gao JQ; Wang H
    Pharm Res; 2021 Aug; 38(8):1397-1404. PubMed ID: 34282500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations.
    He F; Woods CE; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Dec; 100(12):5126-41. PubMed ID: 21789772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.